Tearsheet

Firefly Neuroscience (AIFF)

Market Price (3/29/2026): $2.12 | Market Cap: $28.6 Mil
Sector: Information Technology | Industry: Application Software

Firefly Neuroscience (AIFF)

Market Price (3/29/2026): $2.12
Market Cap: $28.6 Mil
Sector: Information Technology
Industry: Application Software

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15%	Weak multi-year price returns 2Y Excs Rtn is -100%, 3Y Excs Rtn is -147%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -8.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1119%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 958%	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%	Expensive valuation multiples P/SPrice/Sales ratio is 38x
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -56%		Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 106%
3	Megatrend and thematic drivers Megatrends include Neuroscience & Brain Health. Themes include Neurological Diagnostics, AI in Neuroscience, and Neurotherapeutics.		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -972%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -985%
4			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -76%
5			High stock price volatility Vol 12M is 185%
6			Key risks AIFF key risks include [1] a critical cash burn rate with less than one year of cash runway, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 958%
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -56%
3	Megatrend and thematic drivers Megatrends include Neuroscience & Brain Health. Themes include Neurological Diagnostics, AI in Neuroscience, and Neurotherapeutics.
4	Weak multi-year price returns 2Y Excs Rtn is -100%, 3Y Excs Rtn is -147%
5	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
6	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -8.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1119%
7	Expensive valuation multiples P/SPrice/Sales ratio is 38x
8	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 106%
9	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -972%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -985%
10	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -76%
11	High stock price volatility Vol 12M is 185%
12	Key risks AIFF key risks include [1] a critical cash burn rate with less than one year of cash runway, Show more.

Valuation, Metrics & Events

	3/29/26	2025	2024	2023	2022	2021
Share Price CYE	$2.12	$0.88	$2.65	$5.07	$14.40	$148.50
Market Cap CYE ($ Mil)	28.6	11.8	18.8	26.3	-	-
Total Debt ($ Mil)	0.0	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Mil)	4.3	4.3	1.2	0.9	0.0	0.0
Enterprise Value ($ Mil)	24.3	11.8	18.8	26.3
Valuation Ratios
P/S TTM	36.5	15.1	253.6	-	-	-
P/EBIT TTM	-1.4	-0.6	-2.4	-	-	-
P/E TTM	-1.4	-0.6	-2.4	-	-	-
P/FCF TTM	-3.7	-1.5	-3.2	-	-	-
Sector Ratios
P/S TTM (Sector)	3.4	3.6	3.8	3.5	2.9	5.6
P/EBIT TTM (Sector)	7.8	8.9	7.0	3.4	0.7	7.2
P/E TTM (Sector)	5.5	6.0	1.6	0.2	-0.1	8.0
P/FCF TTM (Sector)	12.1	14.7	17.4	15.7	12.5	18.4

	3/29/26	2025	2024
Share Price CYE	$2.12	$0.88	$2.65
Market Cap CYE ($ Mil)	28.6	11.8	18.8
Total Debt ($ Mil)	0.0	0.0	0.0
Total Cash ($ Mil)	4.3	4.3	1.2
Enterprise Value ($ Mil)	24.3	11.8	18.8
Valuation Ratios
P/S TTM	36.5	15.1	253.6
P/EBIT TTM	-1.4	-0.6	-2.4
P/E TTM	-1.4	-0.6	-2.4
P/FCF TTM	-3.7	-1.5	-3.2
Sector Ratios
P/S TTM (Sector)	3.4	3.6	3.8
P/EBIT TTM (Sector)	7.8	8.9	7.0
P/E TTM (Sector)	5.5	6.0	1.6
P/FCF TTM (Sector)	12.1	14.7	17.4

	AIFF	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.0
Rev Chg Q	1,075.8%	7.3%
Rev Chg LTM	958.1%	6.7%
Rev Chg 3Y Avg	958.1%	5.7%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-1,119.4%	18.6%
CFO/Rev LTM	-971.5%	20.7%
Net Inc Mgn	-2,705.9%	12.8%
VALUATION	VERY HIGH
P/S	36.5	3.1
P/CFO	-3.8	14.8
P/FCF	-3.7	19.4
P/E	-1.4	23.7
STABILITY	VERY GOOD
Debt/Equity	0.00	0.22
Cash/Assets	0.35	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Granted Patents	27	5052025	Link
Number of Commercial Users	60	5052025	Link
Proprietary EEG/ERP Database Size	over 180,000 standardized EEG/ERP assessment records	5052025	Link

Upcoming
4/02/2026	Earnings Release	Rev: - EPS: -

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Firefly Neuroscience (AIFF) stock has gained about 25% since 11/30/2025 because of the following key factors:

1. Public-Private Partnership with U.S. Department of War.

Firefly Neuroscience announced a public-private partnership with the Department of War on March 26, 2026, to deploy its FDA 510(k)-cleared, AI-powered EEG/ERP platform for the assessment and treatment of PTSD and TBI in U.S. service members and veterans. This significant expansion into the U.S. government and defense health sectors contributed to a 79.76% increase in the stock price on the day of the announcement, adding approximately $20 million to the company's valuation.

2. Significant Commercial Expansion and NVIDIA GPU Acceleration.

A business update released on March 4, 2026, highlighted Firefly Neuroscience's substantial growth, reporting a 20-fold expansion in its commercial footprint with partner sites reaching 99 by the end of 2025. Concurrently, EEG/ERP scan volumes surged 33-fold to over 10,800 scans in 2025. The company also emphasized its use of NVIDIA L40S GPUs to accelerate its AI-powered "foundation model" initiative, which resulted in a 126.3% jump in the stock on the day of this announcement.

Show more

Stock Movement Drivers

Fundamental Drivers

The 22.5% change in AIFF stock from 11/30/2025 to 3/29/2026 was primarily driven by a 22.5% change in the company's P/S Multiple.

(LTM values as of)	11302025	3292026	Change
Stock Price ($)	1.73	2.12	22.5%
Change Contribution By:
Total Revenues ($ Mil)	1	1	0.0%
P/S Multiple	29.8	36.5	22.5%
Shares Outstanding (Mil)	13	13	0.0%
Cumulative Contribution			22.5%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 3/29/2026

	Return	Correlation
AIFF	26.0%
Market (SPY)	-5.3%	0.9%
Sector (XLK)	-9.1%	5.6%

Fundamental Drivers

The -20.0% change in AIFF stock from 8/31/2025 to 3/29/2026 was primarily driven by a -53.4% change in the company's P/S Multiple.

(LTM values as of)	8312025	3292026	Change
Stock Price ($)	2.65	2.12	-20.0%
Change Contribution By:
Total Revenues ($ Mil)	0	1	82.9%
P/S Multiple	78.4	36.5	-53.4%
Shares Outstanding (Mil)	13	13	-6.1%
Cumulative Contribution			-20.0%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 3/29/2026

	Return	Correlation
AIFF	-17.7%
Market (SPY)	0.6%	5.9%
Sector (XLK)	-0.7%	8.6%

Fundamental Drivers

The -52.6% change in AIFF stock from 2/28/2025 to 3/29/2026 was primarily driven by a -91.5% change in the company's P/S Multiple.

(LTM values as of)	2282025	3292026	Change
Stock Price ($)	4.47	2.12	-52.6%
Change Contribution By:
Total Revenues ($ Mil)	0	1	958.1%
P/S Multiple	427.7	36.5	-91.5%
Shares Outstanding (Mil)	7	13	-47.5%
Cumulative Contribution			-52.6%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2025 to 3/29/2026

	Return	Correlation
AIFF	-51.2%
Market (SPY)	9.8%	15.8%
Sector (XLK)	15.9%	16.7%

Fundamental Drivers

null
null

Market Drivers

2/28/2023 to 3/29/2026

	Return	Correlation
AIFF	-90.6%
Market (SPY)	69.4%	8.8%
Sector (XLK)	94.5%	6.9%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
AIFF Return	241%	-90%	-65%	-48%	-67%	245%	-93%
Peers Return	-22%	-26%	140%	-18%	7%	-6%	14%
S&P 500 Return	27%	-19%	24%	23%	16%	-5%	72%
Monthly Win Rates [3]
AIFF Win Rate	58%	17%	42%	42%	25%	33%
Peers Win Rate	31%	40%	46%	48%	42%	33%
S&P 500 Win Rate	75%	42%	67%	75%	67%	33%
Max Drawdowns [4]
AIFF Max Drawdown	-15%	-92%	-74%	-54%	-67%	-27%
Peers Max Drawdown	-34%	-66%	-36%	-40%	-36%	-13%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-5%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: CBLL, NMTC, STIM, NPCE, LIVN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)

How Low Can It Go

Unique Key	Event	AIFF	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-97.8%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	4542.9%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-54.5%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	119.8%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	80 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-79.5%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	387.6%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	292 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-91.7%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	1100.0%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	247 days	1,480 days

Compare to CBLL, NMTC, STIM, NPCE, LIVN

In The Past

Firefly Neuroscience's stock fell -97.8% during the 2022 Inflation Shock from a high on 3/28/2022. A -97.8% loss requires a 4542.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Firefly Neuroscience (AIFF)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.

AI Analysis | Feedback

Here are 1-3 brief analogies for Firefly Neuroscience (AIFF):

Like Tempus for brain disorders.
Like PathAI for brain diagnostics.
Like Palantir for brain health data analysis.

AI Analysis | Feedback

Brain Network Analytics: A software solution focused on the diagnosis and treatment of various mental illnesses and neurological disorders, including depression, dementia, and anxiety.

AI Analysis | Feedback

Major Customers of Firefly Neuroscience (AIFF)

Firefly Neuroscience sells its solutions primarily to other companies and professional entities. Based on the provided description, its major customers fall into the following categories:

Pharmaceutical Companies: These companies utilize Firefly Neuroscience's Brain Network Analytics (BNA) software, likely for research, development, and clinical applications in the field of mental illnesses and neurological disorders. The description does not list specific names of pharmaceutical companies.
Medical Practitioners: This category includes individual doctors, clinics, and other healthcare organizations. These practitioners use the BNA software for diagnostic and treatment purposes to improve outcomes for patients suffering from conditions such as depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder.

AI Analysis | Feedback

null

AI Analysis | Feedback

Greg Lipschitz, Chief Executive Officer

Greg Lipschitz was appointed CEO of Firefly Neuroscience in March 2025, having previously served as Interim CEO from January 2025 and Executive Chairman from December 2024 to March 2025. He has been on the company's Board since at least December 2022. With over 15 years of experience in private equity, investment banking, capital markets, and advisory roles, he has advised on transactions exceeding $1 billion. His past roles include Managing Director of Old Stone Advisors and former Vice President of Lazer Capital. He is also a Chartered Financial Analyst.

Paul Krzywicki, Chief Financial Officer

Paul Krzywicki has served as the Chief Financial Officer of Firefly Neuroscience since March 2024, after joining the company as Controller in November 2023. He is a licensed CPA with over 15 years of experience in finance and operations. Krzywicki's background includes leadership positions at Nucor Canada, EllisDon, and Canadian Curtis Refrigeration, where he focused on modernization and operating efficiency. He also previously served as Division Controller for a startup company.

Dave DeCaprio, President & COO

Dave DeCaprio was appointed President and Chief Operating Officer of Firefly Neuroscience in April 2025. He is a co-founder of ClosedLoop.ai, which was recognized as the #1 AI Software Solution for Health Care in both 2022 and 2023. DeCaprio brings over 20 years of experience in successfully transitioning advanced technology from academic research laboratories into thriving businesses.

Gil Issachar, Chief Technology Officer

Gil Issachar serves as the Chief Technology Officer at Firefly Neuroscience. He is an accomplished technology leader with over 11 years of experience in software development, algorithm design, data science, and research. Issachar holds a Master's degree in Biomedical Engineering, with his thesis focusing on signal processing and neuroscience.

AI Analysis | Feedback

Key Business Risks for Firefly Neuroscience (AIFF)

Precarious Financial Health and Profitability: Firefly Neuroscience faces significant financial challenges, evidenced by substantial operating losses, negative net income, and a rapid cash burn rate. The company's low revenue, particularly in comparison to its high expenses for research and development and commercialization efforts, raises concerns about its long-term financial viability. An Altman Z-Score of -15.42 indicates a potential risk of bankruptcy, and a Beneish M-Score of 12.58 suggests possible financial manipulation. The stock has also experienced high volatility and has underperformed the broader market and the US Healthcare Services industry.
Regulatory and Clinical Validation Challenges for AI in Mental Health: Operating in the medical technology and artificial intelligence sector for mental health and neurological disorders, Firefly Neuroscience is subject to evolving and stringent regulatory requirements. The rapid advancement of AI in mental health has outpaced scientific validation and regulatory oversight, leading to concerns about the safety, quality, and accountability of AI tools that are not regulated like licensed medical services. There is a risk of AI providing inaccurate, dismissive, or even harmful advice, particularly in crisis situations. The company must navigate complex compliance to avoid fines, recalls, and loss of market access, and demonstrate rigorous clinical validation, ethical transparency, and human oversight for its Brain Network Analytics (BNA™) platform.
Intense Competition and Market Adoption Hurdles: Firefly Neuroscience operates in a crowded and highly competitive neurodiagnostics market. It faces numerous direct competitors offering similar EEG analysis platforms and broader competition from larger technology and medical device companies utilizing AI in neurology. Successfully commercializing new AI-driven solutions and achieving widespread adoption by medical practitioners, who can be conservative in embracing new technologies for sensitive areas like mental health, poses a significant challenge. The market often adopts a "wait and see" attitude towards companies with exciting technology but unproven financials, further complicating market penetration.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable markets for Firefly Neuroscience's main products and services, which include its Brain Network Analytics software for diagnosing and treating mental illnesses and neurological disorders, are substantial on a global scale.

The estimated global market sizes for the relevant areas are as follows:

Global Mental Health Market (Diagnostics and Treatment): The global mental illnesses market size was valued at approximately USD 460.6 billion in 2025 and is projected to reach USD 824.53 billion by 2033. Another report indicates the global mental health market size is expected to be around USD 490.91 billion in 2025, growing to USD 682.51 billion by 2035. The broader global neuroscience market, encompassing diagnostics and treatment for brain disorders, was valued at USD 612 billion in 2022 and is forecast to grow to USD 721 billion by 2026.
Global Neurological Diagnostics Market: This market was estimated at USD 19.01 billion in 2025 and is projected to reach USD 36.57 billion by 2033.
Global Depression Treatment Market: The global anxiety disorders and depression treatment market size was estimated at USD 15.42 billion in 2024 and is projected to reach USD 19.28 billion by 2030.
Global Dementia Treatment Market: This market was estimated at USD 18.03 billion in 2024 and is projected to reach USD 28.11 billion by 2030. Another projection places the global dementia treatment market at USD 19.98 billion in 2025, expected to reach USD 40.64 billion by 2034.
Global Anxiety Disorders Treatment Market: This market is projected to increase from USD 12.33 billion in 2025 to USD 17.56 billion by 2035.
Global Concussion Market (Diagnostics and Treatment): The global concussion market size was estimated at USD 6.58 billion in 2024 and is projected to reach USD 9.31 billion by 2030.
Global Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment Market: The global Attention-Deficit Hyperactivity Disorder (ADHD) market was valued at USD 18.75 billion in 2024 and is expected to reach USD 32.90 billion by 2032. The global ADHD therapeutics market was valued at USD 35.17 billion in 2024 and is projected to reach USD 76.96 billion by 2033.

AI Analysis | Feedback

Firefly Neuroscience, Inc. (AIFF) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

Commercial Footprint Expansion and Partnership Growth: The company has demonstrated significant expansion of its commercial footprint, growing over 20-fold, and has increased its partnerships to 99 commercial sites by the end of 2025. This expanding network of commercial users and partner sites is anticipated to enhance market penetration and broaden access to its neuroscientific solutions.
Increased EEG/ERP Brain Scan Volumes: Directly related to its expansion efforts, Firefly Neuroscience reported a substantial 33-fold increase in EEG/ERP brain scan volumes, reaching over 10,800 scans by the end of 2025. This surge in clinical assessments indicates a rising demand and adoption of its Brain Network Analytics platform, which is expected to translate into higher revenue.
Strategic Acquisition of Evoke Neuroscience: The acquisition of Evoke Neuroscience has been identified as a strategic initiative that has fueled Firefly's commercial reach and increased scan volumes. The integration of Evoke's assets and customer base is expected to continue contributing to the company's revenue growth.
Advancements in AI-Driven Biomarker Discovery and Foundation Model Development: Firefly Neuroscience is leveraging NVIDIA L40S GPU acceleration to advance AI-driven biomarker discovery and is progressing towards developing the world's first EEG/ERP-based foundation model of the human brain. These technological innovations are poised to enhance existing offerings and potentially create new revenue streams through advanced diagnostic and treatment tools.
Expansion of Clinical Applications, particularly ADHD Subtype Identification: The company's AI-powered technology to identify ADHD subtypes represents a specific clinical application that recently garnered significant market attention. Expanding the proven utility of its Brain Network Analytics platform for various mental illnesses and neurological disorders, such as identifying different ADHD subtypes, will open new market opportunities and revenue streams.

AI Analysis | Feedback

Capital Allocation Decisions for Firefly Neuroscience (AIFF)

Share Issuance

In March 2026, Firefly Neuroscience completed an initial private placement, issuing 1.5 million units for $2.25 million. Investors also have the right to purchase up to an additional $18 million in units within 30 days after the initial closing.
In February 2026, the company entered into an At-the-Market (ATM) Offering Agreement, authorizing the sale of up to $7.43 million worth of common stock.
In February 2025, stockholders approved two significant stock issuances as part of a financing strategy from December 2024, involving shares for Helena Special Opportunities LLC and Arena Business Solutions Global SPC II, Ltd.

Inbound Investments

An initial closing in March 2026 generated $2.25 million from accredited investors through a private placement, with an option for these investors to provide up to an additional $18 million.
Stockholder approvals in February 2025 facilitated share issuances to Helena Special Opportunities LLC and Arena Business Solutions Global SPC II, Ltd., representing inbound investments into the company.

Outbound Investments

The company's expansion involved the acquisition of Evoke Neuroscience, Inc.

Capital Expenditures

In the last 12 months as of March 2026, Firefly Neuroscience reported capital expenditures of -$185,000.
The company is focused on expanding its compute capabilities, including the deployment of NVIDIA L40S GPU acceleration for EEG/ERP processing.

Interactive Breakdown

null

null

Better Bets vs. Firefly Neuroscience (AIFF)

null

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Firefly Neuroscience Earnings Notes	12/16/2025
2	Can Firefly Neuroscience Stock Recover If Markets Fall?	10/17/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to AIFF.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
BMI_2282026_Insider_Buying_45D_2Buy_200K	02282026	BMI	Badger Meter	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%
VRNS_2282026_Insider_Buying_45D_2Buy_200K	02282026	VRNS	Varonis Systems	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%
ITRI_2272026_Dip_Buyer_FCFYield	02272026	ITRI	Itron	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
FSLR_2272026_Dip_Buyer_ValueBuy	02272026	FSLR	First Solar	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	0.0%	0.0%	0.0%
PEGA_2272026_Dip_Buyer_ValueBuy	02272026	PEGA	Pegasystems	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	0.0%	0.0%	0.0%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
AGX	Argan	7.8	37.9%	81.1%
TBN	Tamboran Resources	0.9	25.6%	59.4%
U	Unity Software	8.3	13.5%	-56.0%
ADMA	ADMA Biologics	2.2	11.6%	-49.3%
METC	Ramaco Resources	1.0	11.4%	-13.6%
MEOH	Methanex	5.0	9.7%	64.8%
PTON	Peloton Interactive	1.9	8.8%	-28.1%
OXM	Oxford Industries	0.5	8.7%	3.0%
REX	REX American Resources	1.6	8.3%	47.7%
SGML	Sigma Lithium	1.2	7.8%	-20.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
BUR	Burford Capital	0.9	-47.1%	-53.6%
RCKT	Rocket Pharmaceuticals	0.4	-19.6%	7.4%
ZBIO	Zenas BioPharma	0.8	-17.8%	-49.8%
BKSY	BlackSky Technology	0.8	-17.2%	24.2%
PSNL	Personalis	0.6	-13.4%	-20.4%
SLS	SELLAS Life Sciences	0.5	-11.8%	15.8%
ANAB	AnaptysBio	1.6	-11.7%	18.4%
FLY	Firefly Aerospace	2.2	-11.6%	6.0%
INBX	Inhibrx Biosciences	0.9	-11.2%	-26.1%
YOU	Clear Secure	4.6	-11.2%	36.3%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
BCPC	Balchem	5.4	610.4%	8.9%
KOD	Kodiak Sciences	2.0	66.3%	32.3%
OLPX	Olaplex	1.3	51.9%	50.7%
CAR	Avis Budget	5.2	48.6%	15.7%
TBN	Tamboran Resources	0.9	36.0%	59.4%
ELVN	Enliven Therapeutics	2.4	33.8%	152.1%
TROX	Tronox	1.4	30.1%	120.3%
BORR	Borr Drilling	1.8	28.7%	50.1%
BRZE	Braze	2.5	25.5%	-32.9%
INDI	Indie Semiconductor	0.6	24.6%	-9.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
PIPR	Piper Sandler Cos	1.2	-75.2%	-12.4%
BUR	Burford Capital	0.9	-46.2%	-53.6%
WVE	WAVE Life Sciences	1.1	-45.9%	-62.6%
TASK	TaskUs	0.6	-37.8%	-15.9%
MAZE	Maze Therapeutics	1.4	-36.7%	-26.7%
ADMA	ADMA Biologics	2.2	-35.4%	-49.3%
CRCL	Circle Internet	21.5	-25.7%	18.1%
PLAY	Dave & Buster's Entertainment	0.3	-23.5%	-39.5%
EL	Estee Lauder Companies	24.3	-21.8%	-35.6%
NTSK	Netskope	1.9	-18.9%	-55.9%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
SOC	Sable Offshore	1.8	133.2%	104.5%
DAWN	Day One Biopharmaceuticals	2.2	101.0%	129.7%
VG	Venture Global	42.7	85.4%	157.4%
AAOI	Applied Optoelectronics	6.2	82.9%	181.7%
TNGX	Tango Therapeutics	2.1	68.9%	117.4%
AXTI	AXT	2.7	63.3%	270.8%
BW	Babcock & Wilcox Enterprises	1.5	61.7%	134.4%
PARR	Par Pacific	3.3	61.6%	86.9%
LWLG	Lightwave Logic	0.9	61.5%	123.3%
SM	SM Energy	3.8	56.2%	76.5%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.1	-58.6%	-62.6%
BUR	Burford Capital	0.9	-51.4%	-53.6%
OLMA	Olema Pharmaceuticals	1.2	-44.0%	-45.3%
WING	Wingstop	4.3	-43.1%	-35.2%
FRMI	Fermi	3.7	-43.0%	-22.8%
PAR	PAR Technology	0.5	-43.0%	-64.7%
SES	SES AI	0.3	-42.6%	-45.1%
USAS	Americas Gold And Silver	1.5	-41.9%	7.6%
ITRG	Integra Resources	0.4	-41.0%	-36.2%
VITL	Vital Farms	0.6	-40.6%	-58.9%

Peer Comparisons

Peers to compare with:

Financials

	AIFF	CBLL	NMTC	STIM	NPCE	LIVN	Median
Name	Firefly .	CeriBell	NeuroOne.	Neuronet.	NeuroPace	LivaNova
Mkt Price	2.12	17.79	0.73	1.39	13.32	61.84	7.72
Mkt Cap	0.0	0.7	0.0	0.1	0.4	3.4	0.3
Rev LTM	1	89	9	149	100	1,388	95
Op Inc LTM	-9	-58	-8	-31	-16	199	-13
FCF LTM	-8	-42	-6	-21	-11	173	-10
FCF 3Y Avg	-	-	-9	-29	-16	116	-13
CFO LTM	-8	-41	-6	-20	-11	254	-9
CFO 3Y Avg	-	-	-9	-28	-16	171	-13

Growth & Margins

	AIFF	CBLL	NMTC	STIM	NPCE	LIVN	Median
Name	Firefly .	CeriBell	NeuroOne.	Neuronet.	NeuroPace	LivaNova
Rev Chg LTM	958.1%	36.1%	51.6%	99.2%	25.1%	10.7%	43.8%
Rev Chg 3Y Avg	-	-	391.0%	37.9%	30.3%	10.8%	34.1%
Rev Chg Q	1,075.8%	33.7%	-11.7%	85.7%	23.9%	12.1%	28.8%
QoQ Delta Rev Chg LTM	82.9%	7.5%	-4.2%	14.8%	5.4%	2.9%	6.5%
Op Mgn LTM	-1,119.4%	-65.6%	-87.7%	-21.1%	-16.3%	14.4%	-43.3%
Op Mgn 3Y Avg	-	-	-229.1%	-36.7%	-28.3%	8.8%	-32.5%
QoQ Delta Op Mgn LTM	1,340.6%	2.9%	-41.3%	8.1%	2.9%	-0.0%	2.9%
CFO/Rev LTM	-971.5%	-45.8%	-70.7%	-13.7%	-11.0%	18.3%	-29.7%
CFO/Rev 3Y Avg	-	-	-220.4%	-33.3%	-21.2%	13.1%	-27.3%
FCF/Rev LTM	-984.9%	-46.7%	-71.8%	-14.2%	-11.3%	12.5%	-30.5%
FCF/Rev 3Y Avg	-	-	-226.3%	-35.3%	-21.5%	8.9%	-28.4%

Valuation

	AIFF	CBLL	NMTC	STIM	NPCE	LIVN	Median
Name	Firefly .	CeriBell	NeuroOne.	Neuronet.	NeuroPace	LivaNova
Mkt Cap	0.0	0.7	0.0	0.1	0.4	3.4	0.3
P/S	36.5	7.4	4.2	0.6	4.4	2.4	4.3
P/EBIT	-1.4	-12.8	-5.4	-3.0	-31.8	-19.7	-9.1
P/E	-1.4	-12.4	-5.4	-2.5	-20.7	-13.9	-8.9
P/CFO	-3.8	-16.2	-5.9	-4.7	-40.4	13.3	-5.3
Total Yield	-72.0%	-8.1%	-18.6%	-43.9%	-4.8%	-7.2%	-13.3%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	-	-	-26.7%	-39.1%	-4.9%	4.0%	-15.8%
D/E	0.0	0.0	0.0	0.9	0.2	0.1	0.1
Net D/E	-0.2	-0.2	-0.1	0.6	0.0	-0.1	-0.1

Returns

	AIFF	CBLL	NMTC	STIM	NPCE	LIVN	Median
Name	Firefly .	CeriBell	NeuroOne.	Neuronet.	NeuroPace	LivaNova
1M Rtn	204.0%	-4.7%	8.9%	3.7%	-8.6%	-12.4%	-0.5%
3M Rtn	96.3%	-16.5%	0.1%	-2.1%	-16.9%	-1.6%	-1.9%
6M Rtn	-25.9%	56.5%	-20.5%	-48.7%	30.6%	15.7%	-2.4%
12M Rtn	-48.4%	-8.6%	-15.1%	-63.1%	12.4%	58.0%	-11.8%
3Y Rtn	-75.6%	-28.8%	-53.8%	-52.2%	170.7%	44.8%	-40.5%
1M Excs Rtn	214.2%	-0.4%	13.5%	6.3%	-3.5%	-5.1%	2.9%
3M Excs Rtn	100.6%	-8.8%	3.4%	6.6%	-9.6%	6.2%	4.8%
6M Excs Rtn	-23.2%	61.0%	-15.2%	-44.1%	36.6%	21.9%	3.3%
12M Excs Rtn	-61.2%	-20.6%	-28.4%	-78.3%	-6.8%	43.5%	-24.5%
3Y Excs Rtn	-145.6%	-90.7%	-112.8%	-119.0%	192.5%	-19.5%	-101.7%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Filing Date	11/12/2025	4/3/2025	4/3/2025	2/2/2024	2/2/2024
Key Financials
Total Revenue	1	0	0	0	0
EBITDA	-21	-10	-3	-3	-4
Operating Income	-9	-9	-3	-3	-5
Net Income	-21	-10	-3	-4	-4
EPS	-2.53	-1.60	-0.50	-0.73	-0.84
Growth Rates
Total Revenue Growth	958.1%	-78.3%	∞%	-100.0%	-
EBITDA Growth	-170.3%	-299.5%	19.3%	16.1%	-
Operating Income Growth	-7.1%	-198.2%	5.4%	29.6%	-
Net Income Growth	-173.3%	-301.8%	31.3%	13.5%	-
Margins
EBITDA Margin	-2658.5%	-9557.4%	-518.9%	-	-11928.1%
Operating Income Margin	-1119.4%	-8500.0%	-618.1%	-	-14437.5%
Net Income Margin	-2705.9%	-9685.2%	-522.7%	-	-13690.6%
Cash & Debt
Total Cash	4	2	2	0	1
Total Debt	0	1	0	0	2
Net Debt / (Cash)	-4	-1	-2	-0	1
Cash Flows
Net Cash from Operations	-8	-6	-2	-3	-4
Free Cash from Operations	-8	-7	-3	-3	-4
Returns to Shareholders
Dividends	0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023
Filing Date	11/12/2025	8/13/2025	5/14/2025	4/3/2025	11/14/2024	8/19/2024	5/14/2025	4/3/2025	2/2/2024	8/19/2024
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	2
Ebitda	-3	-2	-13	-4	-4	-1	-1	-1	-1	1
Operating Income	-3	-2	-2	-3	-4	-1	-1	-2	-1	-1
Net Income	-3	-2	-13	-4	-4	-1	-1	-1	-1	0
EPS	-0.20	-0.14	-1.74	-0.45	-0.61	-0.16	-0.22	-0.21	-0.13	0.05
Key Financials TTM
Total Revenue TTM	1	0	0	0	0	0	2	2	-	-
Ebitda TTM	-21	-23	-22	-10	-8	-4	-2	-2	-	-
Operating Income TTM	-9	-11	-10	-9	-8	-5	-4	-4	-	-
Net Income TTM	-21	-23	-22	-10	-8	-4	-3	-2	-	-
Growth Rates Quarterly
Total Revenue Growth	1075.8%	2890.0%	258.3%	178.9%	43.5%	-99.5%	-	-	-	-
EBITDA Growth	39.7%	-41.7%	-1041.3%	-244.6%	-558.6%	-328.6%	-48.5%	-	-	-
Operating Income Growth	41.3%	-29.8%	-89.3%	-63.5%	-559.7%	-105.3%	-43.6%	-	-	-
Net Income Growth	38.5%	-45.0%	-1052.4%	-251.4%	-559.8%	-638.4%	-39.9%	-	-	-
Margins Quarterly
EBITDA Margin	-662.6%	-592.3%	-29727.9%	-6964.2%	-12912.1%	-12500.0%	-9333.3%	-5636.8%	-2813.0%	27.0%
Operating Income Margin	-645.4%	-546.5%	-4802.3%	-4834.0%	-12933.3%	-12590.0%	-9091.7%	-8247.4%	-2813.0%	-30.3%
Net Income Margin	-680.2%	-613.0%	-30069.8%	-7141.5%	-12997.0%	-12640.0%	-9350.0%	-5668.4%	-2826.1%	11.6%
Cash & Debt
Total Cash	4	6	10	2	1	0	-	2	1	-
Total Debt	0	0	0	1	0	0	0	0	0	0
Net Debt / (Cash)	-4	-6	-10	-1	-1	0	-	-2	-1	-
Cash Flows Quarterly
FCF from Operations	-1	-2	-3	-1	-3	-1	-1	-1	0	-
Cash Flows TTM
FCF from Operations TTM	-8	-9	-7	-6	-5	-2	-	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-8.8%	-5.8%	-8.3%	-12.0%	-20.1%	-14.5%	-	-8.4%	-3.5%	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-7.7%	-9.4%	-10.1%	-10.7%	-9.6%	-13.1%	-	-4.8%	-	-

Segment Financials

Revenue by Segment

$ Mil	2024
Analytical reports	0
Service	0
Total	0

Price Behavior

Price Behavior

Market Price	$2.18
Market Cap ($ Bil)	0.0
First Trading Date	01/03/2007
Distance from 52W High	-47.0%
	50 Days	200 Days
DMA Price	$1.24	$2.05
DMA Trend	down	up
Distance from DMA	75.8%	6.2%
	3M	1YR
Volatility	354.3%	186.6%
Downside Capture	0.51	1.94
Upside Capture	573.75	161.42
Correlation (SPY)	1.2%	13.7%

AIFF Betas & Captures as of 2/28/2026

	1M	2M	3M	6M	1Y	3Y
Beta	2.59	3.15	2.91	2.70	1.80	1.38
Up Beta	2.42	2.84	2.79	1.57	1.49	0.79
Down Beta	3.58	2.55	2.56	2.96	1.46	1.51
Up Capture	37%	243%	10%	61%	119%	42%
Bmk +ve Days	9	20	31	70	142	431
Stock +ve Days	8	16	21	51	111	332
Down Capture	402%	389%	430%	299%	168%	113%
Bmk -ve Days	12	21	30	54	109	320
Stock -ve Days	13	24	38	68	132	404

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AIFF
AIFF	-46.3%	185.9%	0.30	-
Sector ETF (XLK)	22.4%	26.8%	0.73	14.5%
Equity (SPY)	14.5%	18.9%	0.59	13.6%
Gold (GLD)	50.2%	27.7%	1.46	0.3%
Commodities (DBC)	17.8%	17.6%	0.85	16.1%
Real Estate (VNQ)	0.4%	16.4%	-0.15	14.4%
Bitcoin (BTCUSD)	-23.7%	44.2%	-0.49	20.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AIFF
AIFF	-52.3%	174.9%	0.24	-
Sector ETF (XLK)	15.4%	24.6%	0.56	8.5%
Equity (SPY)	11.8%	17.0%	0.54	10.5%
Gold (GLD)	20.7%	17.7%	0.96	2.5%
Commodities (DBC)	11.6%	18.9%	0.50	4.6%
Real Estate (VNQ)	3.0%	18.8%	0.07	11.1%
Bitcoin (BTCUSD)	4.0%	56.6%	0.29	4.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AIFF
AIFF	-18.2%	175.1%	0.51	-
Sector ETF (XLK)	20.8%	24.3%	0.79	7.2%
Equity (SPY)	14.0%	17.9%	0.67	8.6%
Gold (GLD)	13.3%	15.8%	0.70	2.2%
Commodities (DBC)	8.2%	17.6%	0.39	2.6%
Real Estate (VNQ)	4.7%	20.7%	0.19	7.7%
Bitcoin (BTCUSD)	66.4%	66.8%	1.06	3.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3132026
Short Interest: Shares Quantity	1.6 Mil
Short Interest: % Change Since 2282026	300.2%
Average Daily Volume	46.0 Mil
Days-to-Cover Short Interest	1
Basic Shares Quantity	13.5 Mil
Short % of Basic Shares	11.5%

Returns Analyses

	Title
0	Can Firefly Neuroscience Stock Recover If Markets Fall?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/15/2024	-5.7%	-5.7%	-13.2%
11/21/2022	-21.1%	-28.2%	-44.7%
8/15/2022	9.1%	11.6%	-4.1%
4/18/2022	5.0%	1.3%	-35.4%
11/3/2021	-9.5%	-13.8%	-9.7%
8/18/2021	-3.8%	3.8%	15.0%
5/18/2021	-2.6%	7.7%	31.9%
2/17/2021	17.6%	4.0%	45.7%
...
SUMMARY STATS
# Positive	5	7	5
# Negative	5	3	5
Median Positive	9.1%	7.7%	45.7%
Median Negative	-5.7%	-13.8%	-13.2%
Max Positive	51.5%	27.3%	106.1%
Max Negative	-21.1%	-28.2%	-44.7%

	Forward Returns
11/15/2024	-5.7%	-5.7%	-13.2%
11/21/2022	-21.1%	-28.2%	-44.7%
8/15/2022	9.1%	11.6%	-4.1%
4/18/2022	5.0%	1.3%	-35.4%
11/3/2021	-9.5%	-13.8%	-9.7%
8/18/2021	-3.8%	3.8%	15.0%
5/18/2021	-2.6%	7.7%	31.9%
2/17/2021	17.6%	4.0%	45.7%
11/16/2020	6.3%	26.6%	50.6%
8/18/2020	51.5%	27.3%	106.1%
SUMMARY STATS
# Positive	5	7	5
# Negative	5	3	5
Median Positive	9.1%	7.7%	45.7%
Median Negative	-5.7%	-13.8%	-13.2%
Max Positive	51.5%	27.3%	106.1%
Max Negative	-21.1%	-28.2%	-44.7%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
09/30/2025	11/12/2025	10-Q
06/30/2025	08/13/2025	10-Q
03/31/2025	05/14/2025	10-Q
12/31/2024	04/03/2025	10-K
09/30/2024	11/14/2024	10-Q
06/30/2024	08/19/2024	10-Q
09/30/2023	02/02/2024	S-4/A

Recent Forward Guidance [BETA]

Latest: null Earnings Reported N/A/N/A/N/A | Prior: null Earnings Reported N/A/N/A/N/A

null

Insider Activity

Expand for More

#	Owner	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Windsor, Private Capital Lp	See footnote	Sell	10222025	2.46	33,500	82,310	3,277,702	Form
2	Windsor, Private Capital Lp	See footnote	Sell	10222025	2.40	19,222	46,140	3,156,056	Form
3	Windsor, Private Capital Lp	See footnote	Sell	10222025	2.07	78,031	161,735	2,563,459	Form
4	Windsor, Private Capital Lp	See footnote	Sell	10172025	2.74	17,500	48,027	3,986,793	Form
5	Windsor, Private Capital Lp	See footnote	Sell	10172025	2.65	40,139	106,457	3,746,397	Form

AIFF Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing AIFF?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What AIFF Makes & Who Pays

TTM figures based on

AIFF Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Firefly Neuroscience (AIFF)

Market Price (3/29/2026): $2.12 | Market Cap: $28.6 MilSector: Information Technology | Industry: Application Software

Firefly Neuroscience (AIFF)

Market Price (3/29/2026): $2.12Market Cap: $28.6 MilSector: Information TechnologyIndustry: Application Software

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Firefly Neuroscience (AIFF)

Major Customers of Firefly Neuroscience (AIFF)

Key Business Risks for Firefly Neuroscience (AIFF)

Capital Allocation Decisions for Firefly Neuroscience (AIFF)

Share Issuance

Inbound Investments

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets vs. Firefly Neuroscience (AIFF)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance [BETA]

Insider Activity

AIFF Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

Market Price (3/29/2026): $2.12 | Market Cap: $28.6 Mil
Sector: Information Technology | Industry: Application Software

Market Price (3/29/2026): $2.12
Market Cap: $28.6 Mil
Sector: Information Technology
Industry: Application Software